Clinical trials: Meningitis, Meningococcal
Diphtheria, Tetanus and Acellular Pertussis, Epidemic Meningitis
Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine
This clinical trial is conducted in two parts. Part One employs a randomized, partially blinded, dose-escalation, partially active-controlled design. Part Two utilizes a randomized, blinded, placebo-controlled design.
- Conditions
- Diphtheria, Tetanus and Acellular Pertussis, Epidemic Meningitis, Haemophilus Influenzae Type B Infection
- Trial name
- NCT07203755
- Testing
- Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis-Haemophilus influenzae type b (Conjugate)-Meningococcal Group ACYW135 (Conjugate) Combined Vaccine (DTcP-Hib-MCV4), DTcP-Hib-MCV4, Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis (DTcP)
- Where
- China
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Meningococcal Meningitis
A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds
This is a randomized, observer-blind, peer-controlled study. There will be 2 treatment groups, screened subjects were given study numbers in the order of enrollment and randomly assigned to the test and control groups in a 1:1…
- Trial name
- NCT06226714
- Testing
- MCV4, MPSV4
- Where
- 3 sites in China
- Volunteers
- 840 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Epidemic Meningitis
A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a 4 to 6 Year-old Population
The scientific name of meningococcus is Neisseria meningitidis (Nm), the causative agent of epidemic meningococcal meningitis (rheumatoid encephalitis), which colonizes the mucous membranes of the human nasopharynx or causes…
- Trial name
- NCT06011200
- Testing
- MCV4, MSPV4
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Meningitis, Meningococcal, Sequela
Long-term Sequelae of Childhood Meningitis and Meningococcal Purpura Fulminans
While the initial evolution of meningococcal meningitis (MM) is well described, there are few data on the long-term evolution, beyond 1 year.
- Trial name
- SEINE (NCT04685850)
- Testing
- sequela evaluation
- Where
- 9 sites in France
- Volunteers
- 43 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Meningitis, Meningococcal
Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month Olds
Out of the 13 identified serogroups of Neisseria meningitidis (Nm) the six serogroups (A, B, C, W, Y and X) are responsible for majority of infections.
- Trial name
- NCT03295318
- Testing
- Non-adjuvanted study formulation NmCV-5, Adjuvanted study formulation NmCV-5, Menactra
- Where
- Mali
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Meningitis, Meningococcal
A Human Controlled Infection Study with Neisseria Lactamica in Malian Adults
This study is part of a series of projects to improve protection against meningitis. Previously, researchers have given nose drops containing N.
- Trial name
- NCT04665791
- Testing
- Intranasal inoculation with Neisseria lactamica
- Where
- Mali
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Center for Vaccine Development - Mali
Serogroup C Meningococcal Meningitis, Diphtheria
Sero-epidemiological Survey of England in 2019/2020 - COVID-19
This is a pilot study to assess the feasibility of establishing a national sero-epidemiological survey in England in individuals aged 0-24 years, focusing on assessing humoral immunity against diphtheria, Group C invasive…
- Conditions
- Serogroup C Meningococcal Meningitis, Diphtheria, COVID-19
- Trial name
- STORY (NCT04061382)
- Testing
- Venepuncture, Oral fluid swab
- Where
- United Kingdom
- Volunteers
- 2,963 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Infections, Meningococcal
Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age
The purpose of this study is to evaluate the immunogenicity, safety and tolerability of rMenB+OMV NZ and MenACWY vaccines when concomitantly administered to healthy subjects 16-18 years of age.
- Trial name
- NCT04318548
- Testing
- Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ), Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid)
- Where
- 53 sites in United States, Italy
- Volunteers
- 945 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningococcal Infections
Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe
Primary objective: This study aimed to demonstrate the non-inferiority of the antibody response against meningococcal serogroups A, C, Y, and W following the administration of a 3-dose series of MenACYW conjugate vaccine compared…
- Trial name
- NCT03547271
- Testing
- MenACYW conjugate vaccine, Meningococcal group A, C, W-135, and Y conjugate vaccine, DTaP-IPV-HB-Hib vaccine
- Where
- 33 sites in Czechia, Finland and 5 more
- Volunteers
- 1,660 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Healthy Volunteers (Meningococcal Infection)
Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US
The purpose of this study was to compare the immunogenicity and describe the safety of MenACYW conjugate vaccine and MENVEO® when both are administered concomitantly with routine pediatric vaccines to healthy infants and toddlers…
- Trial name
- NCT03537508
- Testing
- MenACYW conjugate vaccine, MenACYW-135 conjugate vaccine, DTaP-IPV//Hib vaccine
- Where
- 70 sites in United States, Puerto Rico
- Volunteers
- 2,627 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningitis, Meningococcal
Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine
The purpose of this study was to assess immunogenicity and safety of MenABCWY vaccine in healthy adolescents and adults aged 15 to 25 years previously vaccinated with MenACWY vaccine.
- Trial name
- NCT04707391
- Testing
- MenABCWY vaccine, MenACWY vaccine, MenB vaccine
- Where
- 69 sites in United States, Argentina and 2 more
- Volunteers
- 1,250 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningitis, Meningococcal
Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months
The purpose of this study is to evaluate the immunogenicity and safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in healthy volunteers aged from 3 to 5 months.
- Trial name
- NCT05252715
- Testing
- Meningococcal ACYW135 Polysaccharide Conjugate Vaccine, Meningococcal A and C Polysaccharide Conjugate Vaccine
- Where
- 2 sites in China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Meningococcal Meningitis
A Study of the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine
The purpose of this study was to explore the safety and immunogenicity of the experimental vaccine compared with the control vaccines.
- Trial name
- NCT06337071
- Testing
- ACYW135 Meningococcal Polysaccharide Conjugate Vaccine, ACYW135 Meningococcal Polysaccharide Vaccine
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Aimei Vacin BioPharm (Zhejiang) Co., Ltd.
Infections, Meningococcal
Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults
The purpose of this study was to evaluate the effectiveness of 2 doses or 3 doses of GSK's licenced meningococcal group B Bexsero (rMenB+OMV NZ) vaccine and of 2 doses of GSK's investigational combined meningococcal (MenABCWY)…
- Trial name
- NCT04502693
- Testing
- rMenB+OMV NZ vaccine, Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY), MenABCWY-1
- Where
- 112 sites in United States, Australia and 5 more
- Volunteers
- 3,657 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningitis, Meningococcal
A Sourcing Study to Collect Human Blood Samples From Healthy Adults
The purpose of this study was to collect large volumes of matched pairs of pre- and post-vaccination sera from healthy subjects who administered GlaxoSmithKline (GSK) Biologicals' vaccine against meningitis- MenACWY vaccine…
- Trial name
- NCT03493919
- Testing
- rMenB+OMV NZ vaccine, Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)
- Where
- 6 sites in Australia, Germany
- Volunteers
- 1,021 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Neisseria Meningitides Meningitis
A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years
This is a phase IV, single-center, observer-blind, randomized, controlled vaccine trial in 2 to 10 years old healthy subjects. Each participant will receive a single intramuscular injection of one of the two vaccines either MPV…
- Trial name
- NCT04450498
- Testing
- Yuxi Walvax MPV ACYW® vaccine, Sanofi Pasteur Menactra® vaccine
- Where
- Mali
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Walvax Biotechnology Co., Ltd.
Meningococcal Disease
Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia
To evaluate the immune response and safety following a single dose of Novartis Meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy children, adolescents and adults in Russia.
- Trial name
- NCT01725217
- Testing
- MenACWY-CRM
- Where
- 4 sites in Russia
- Volunteers
- 198 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Meningococcal Infections, Neisseria Meningitis Sepsis
The Long-term Impact of Invasive Meningococcal Disease in Australian Adolescents and Young Adults
Survivors of invasive meningococcal disease (IMD) experience a range of mild to severe sequelae that impact upon their quality of life.
- Conditions
- Meningococcal Infections, Neisseria Meningitis Sepsis, Neisseria Infection
- Trial name
- AMEND (NCT03798574)
- Where
- 4 sites in Australia
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- University of Adelaide
Meningococcal Vaccine, rLP2086
A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.
This study is to look at a new vaccine that might prevent meningococcal disease, and to look at the safety of the new vaccine as well as how it is tolerated when given together with Repevax.
- Conditions
- Meningococcal Vaccine, rLP2086, Repevax, N Meningitidis Serogroup B
- Trial name
- NCT01323270
- Testing
- rLP2086, Repevax, Saline
- Where
- 36 sites in Finland, Germany and 1 more
- Volunteers
- 753 people, healthy volunteers welcome
- Sponsor
- Pfizer
Meningitis, Meningococcal Meningitis
Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian Federation
The aim of this study is to generate local data on the safety of Menactra® in individuals 2 to 55 years of age in the Russian Federation.
- Conditions
- Meningitis, Meningococcal Meningitis, Meningococcal Infections
- Trial name
- NCT02699840
- Testing
- Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
- Where
- Russia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company